[18F]FE-PE2I

[18F]FE-PE2I is a PET radioligand specifically designed for **in vivo imaging of the dopamine transporter (DAT)** in the brain. It is a cocaine derivative and demonstrates high affinity and selectivity for DAT with minimal off-target binding to other monoaminergic transporters. Compared to earlier agents ([11C]PE2I), [18F]FE-PE2I offers faster kinetics, improved spatial resolution due to the properties of fluorine-18, and produces fewer interfering radiometabolites, resulting in more accurate quantitative DAT imaging. Its use is established in the diagnostic evaluation of **Parkinson’s disease and other parkinsonian syndromes**, where it helps detect presynaptic dopamine deficiency. It is suitable for clinical routine due to its GMP-compliant automated production and provides robust, reproducible PET results in both research and clinical settings[1][2][3][4][5][6].

Other names

(E)-N-(3-iodoprop-2-enyl)-2beta-carbofluoroethoxy-3beta-(4'-methyl-phenyl) nortropane